Video Library

Search the Video Library

Filter by Date

Displaying Results 16 - 27 of 27

GRACE joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies. Jennifer Brown, MD, PhD, Director of the CLL Center at the Dana-Farber Cancer Institute spoke with GRACE and provided a provoking and educational discussion on FCR vs

GRACE joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies. Joshua Brody, MD, Oncologist and Director, Assistant Professor of Medicine, Hematology & Medical Oncology at Mount Sinai Hospital spoke with GRACE about the question

GRACE joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies. John Kuruvilla, MD, Associate Professor, Princess Margaret Hospital, University Health Network in Toronto, Canada, spoke with GRACE about Chronic Lymphocytic Leukemia

¿Todos los linfomas difusos de linfocitos B (DLBCL) están hechos iguales?

GRACE sat down with Dr. Marco Ruiz to discuss information regarding all diffuse large B-cell lymphoma (DLBCL) and are they made equally ("¿Todos los linfomas difusos de linfocitos B (DLBCL) están hechos iguales?"). Stay tuned for more on our continuing video series with our Spanish speaking faculty

¿Cuál es el rol de vigilancia imagenológica en linfomas indolentes y en la leucemia crónica linfocítica?

GRACE sat down with Dr. Marco Ruiz to discuss information regarding the role of surveillance imaging in indolent lymphomas and chronic lymphocytic leukemia (CLL) (¿Cuál es el rol de vigilancia imagenológica en linfomas indolentes y en la leucemia crónica linfocítica?). Stay tuned for more on our

¿Están activos moléculas inhibitorias como el de la muerte programada 1 (PD1) y el ligando de muerte programada 1 (PDL1) en el linfoma y en la leucemia linfocítica crónica (LLC)?

GRACE sat down with Dr. Marco Ruiz to discuss information regarding inhibitory molecules like the programmed cell death protein 1 (PD1) and its ligand (PDL1), and if they are active in lymphoma and in chronic lymphocytic leukemia (¿Están activos moléculas inhibitorias como el de la muerte programada

Bladder Cancer Video Series with Hosted by Ramy Sedhom, MD, with guest faculty Dr. Elizabeth Kessler - Muscle Invasive Bladder Cancer in the Elderly Pt 2

We are excited to bring you new information on our Bladder Cancer Program, hosted by Ramy Sedhom, MD. For this video, Dr. Ramy Sedhom furthers his discussion with Dr. Elizabeth Kessler, from the University of Colorado Cancer Center. For more information on Dr. Kessler, please visit her bio here. In

Bladder Cancer Series Hosted by Dr. Sedhom, with Dr. Petros Grivas - Muscle Invasive Bladder Cancer

We are excited to bring you new information on our Bladder Cancer Program, hosted by Ramy Sedhom, MD. For this video, Dr. Ramy Sedhom introduces us to Dr. Petros Grivas, from the University of Washington and the Fred Hutchinson Cancer Center. For more information on Dr. Grivas, please visit his bio

We are happy to bring you updates to the GRACE Blood Cancer Video Library. For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Assistant Professor of Medicine, Hematology and Medical Oncology and Director of the Lymphoma Immunotherapy Program at the Icahn School of Medicine at Mount Sinai

We are happy to bring you updates to the GRACE Blood Cancer Video Library. For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Assistant Professor of Medicine, Hematology and Medical Oncology and Director of the Lymphoma Immunotherapy Program at the Icahn School of Medicine at Mount Sinai

We are happy to bring you updates to the GRACE Blood Cancer Video Library. For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Assistant Professor of Medicine, Hematology and Medical Oncology and Director of the Lymphoma Immunotherapy Program at the Icahn School of Medicine at Mount Sinai

¿Cuáles son los riesgos y beneficios de ibrutinib y de idelalisib? ¿Cómo manejamos los efectos secundarios de los nuevos inhibidores de la tirosina cinasa?

GRACE sat down with Dr. Marco Ruiz to discuss "What are the risks and benefits of Ibrutinib and Idelalisib?" for our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments.